217 related articles for article (PubMed ID: 27063625)
1. Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.
Fragoso YD; Gama PDD; Gomes S; Khouri JMN; Matta APDC; Fernanda Mendes M; Stella CRAV
Mult Scler Relat Disord; 2016 Mar; 6():64-65. PubMed ID: 27063625
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
4. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
[TBL] [Abstract][Full Text] [Related]
5. Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption.
De Masi R; Accoto S; Orlando S; De Blasi V; Pasca S; Scarpello R; Spagnolo L; Idolo A; De Donno A
BMC Neurol; 2015 Jul; 15():125. PubMed ID: 26227815
[TBL] [Abstract][Full Text] [Related]
6. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
[TBL] [Abstract][Full Text] [Related]
7. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Ann Neurol; 2020 May; 87(5):688-699. PubMed ID: 32056253
[TBL] [Abstract][Full Text] [Related]
8. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
9. Melanoma during fingolimod treatment for multiple sclerosis.
Velter C; Thomas M; Cavalcanti A; Bastien M; Chochon F; Lubetzki C; Routier E; Robert C
Eur J Cancer; 2019 May; 113():75-77. PubMed ID: 30986706
[No Abstract] [Full Text] [Related]
10. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
Naegelin Y; Rasenack M; Andelova M; Von Felten S; Fischer-Barnicol B; Amann M; Mehling M; Kappos L; Sprenger T; Derfuss T
Mult Scler Relat Disord; 2018 Oct; 25():14-20. PubMed ID: 30014876
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Barbin L; Rousseau C; Jousset N; Casey R; Debouverie M; Vukusic S; De Sèze J; Brassat D; Wiertlewski S; Brochet B; Pelletier J; Vermersch P; Edan G; Lebrun-Frenay C; Clavelou P; Thouvenot E; Camdessanché JP; Tourbah A; Stankoff B; Al Khedr A; Cabre P; Papeix C; Berger E; Heinzlef O; Debroucker T; Moreau T; Gout O; Bourre B; Créange A; Labauge P; Magy L; Defer G; Foucher Y; Laplaud DA;
Neurology; 2016 Feb; 86(8):771-8. PubMed ID: 26826205
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
Puz P; Lasek-Bal A
Med Sci Monit; 2016 Nov; 22():4277-4282. PubMed ID: 27829656
[TBL] [Abstract][Full Text] [Related]
13. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
14. Novel Agents for Relapsing Forms of Multiple Sclerosis.
Straus Farber R; Harel A; Lublin F
Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
[TBL] [Abstract][Full Text] [Related]
15. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
[TBL] [Abstract][Full Text] [Related]
16. Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.
Bedri SK; Nilsson OB; Fink K; Månberg A; Hamsten C; Ayoglu B; Manouchehrinia A; Nilsson P; Olsson T; Hillert J; Grönlund H; Glaser A
PLoS One; 2019; 14(5):e0217208. PubMed ID: 31141529
[TBL] [Abstract][Full Text] [Related]
17. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Oshima Y; Tanimoto T; Yuji K; Tojo A
Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis treatment effects on plasma cytokine receptor levels.
Bedri SK; Fink K; Manouchehrinia A; Lundström W; Kockum I; Olsson T; Hillert J; Glaser A
Clin Immunol; 2018 Feb; 187():15-25. PubMed ID: 28941836
[TBL] [Abstract][Full Text] [Related]
19. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
[TBL] [Abstract][Full Text] [Related]
20. Immune thrombocytopenic purpura associated with fingolimod.
Yuen HLA; Brown S; Chan N; Grigoriadis G
BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28893804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
